Abeona Therapeutics Reports on Initial Safety and Biopotency Signals in MPS IIIB Gene Therapy Clinical Trial
February 07, 2018 08:45 ET
|
Abeona Therapeutics Inc.
First-in-man AAV9-based gene therapy delivered by single intravenous injection targeting central nervous system and peripheral manifestations of MPS IIIB.ABO-101 is well tolerated and demonstrates...
Abeona Therapeutics Enrolls First Patient in ABO-101 Phase 1/2 Clinical Trial for MPS IIIB
December 20, 2017 08:45 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Dec. 20, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell...
Abeona Reports Third Quarter 2017 Financial Results and Recent Business Highlights
November 15, 2017 08:25 ET
|
Abeona Therapeutics Inc.
Investor Conference Call to be held Monday, November 20th at 10:00 am ETGlobal enrollment continues in ABO-102 trial for MPS IIIAScreening initiated in ABO-101 Phase 1/2 trial for MPS IIIBPivotal...
Abeona Enrolls First Subject in Spain in Ongoing Phase 1/2 Clinical Trial in MPS IIIA
November 09, 2017 08:45 ET
|
Abeona Therapeutics Inc.
Company Opens European Subsidiary in Spain to Support Global Clinical DevelopmentNine subjects at global clinical sites enrolled to date with more than 2,000 days cumulative follow up assessed NEW...
Abeona Therapeutics Enrolls First Two Patients in Pivotal Expansion of Phase 1/2 Clinical Trial in MPS IIIA
October 11, 2017 08:19 ET
|
Abeona Therapeutics Inc
ABO-102 Patients Enrolled in Cohort 3 at 3E13 vg/kgAccelerated enrollments begin with first Patient Enrolled at clinical site in Australia; Patient Screening at Spain site underwayDay 30 results...
Abeona Therapeutics and Brammer Bio Announce Collaboration for Commercial Translation of ABO-102
September 28, 2017 08:32 ET
|
Abeona Therapeutics Inc
--Strategic alignment with Brammer Bio for commercial AAV process development, scale up and assay validation --Phillip B. Maples, Ph.D., to lead Abeona manufacturing, as VP of Therapeutics...
Voyager Therapeutics Announces Publication from the California Institute of Technology of a Second-Generation Gene Therapy Capsid Demonstrating Further Enhanced Gene Transfer to the Brain
July 17, 2017 07:04 ET
|
Voyager Therapeutics
A single, intravenous administration of a novel AAV capsid provided up to 100-fold increase in gene transfer to the central nervous system in a preclinical model compared to the historical standard...